Abstract 349P
Background
Euphorbia hirta has many health benefits for enhancing human health. It exhibits various antioxidant properties. Our aim was to investigate the effects of several polyphenols from Euphorbia hirta ethanolic extract on the growth and metastatic potential of B16F10 melanoma cells in vitro and to measure the observable changes of cell morphology upon exposure to the extract.
Methods
The cytotoxic activity of the Euphorbia hirta extract on B16F10 melanoma cell line was investigated in vitro using 3‐ (4, 5‐dimethyl thiazol‐2yl) ‐2, 5‐diphenyl tetrazolium bromide (MTT). B16F10 (human Melanoma) cell lines were cultured in DMEM supplemented with 10% inactivated Fetal Bovine Serum (FBS), penicillin (100 IU/ml), streptomycin (100 μg/ml) and amphotericin B (5 μg/ml) in an humidified atmosphere of 5% CO2 at 37 °C until confluent. The cells were dissociated with Trypsin solution (0.2% trypsin, 0.02% EDTA in PBS). The stock cultures were grown in 25 cm2 culture flasks and all experiments were carried out in 96 micro-titer plates. After culturing and proliferation of B16F10 cells, these cells were exposed to various ethanolic extract of E hirta. The potency of plant extract concentration was calculated in terms of a percent decrease in viable B16F10 cells as compared to the control value.
Results
The in vitro growth of B16F10 melanoma cells in the presence of a series of polyphenolic compounds (10–9 to 10–5 M) was evaluated. Quercetin, apigenin, EGCG, resveratrol, curcumin, and tamoxifen inhibited the growth of B16F10 cells in a concentration‐dependent manner. The concentrations needed to inhibit cell growth by 50% (IC50) are reported. The results of MTT assay test showed that the ethanol extract of Euphorbia hirta was tested for the anticancer activity and it showed the most effective inhibition of B16F10 cells proliferation.
Conclusions
We assessed the cytotoxic effect of Euphorbia hirta extract in cell culture. In defiance of astonishing advances in modern medicine, such as surgery, radiotherapy, chemotherapy, and immunotherapy, melanoma cancer disease remains a worldwide health problem, thus endeavoring the search for a new alternate approach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract